Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
LabCorp of America, Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, Florida, USA.
Cancer Cytopathol. 2024 Aug;132(8):491-498. doi: 10.1002/cncy.22820. Epub 2024 Apr 9.
The atypia of undetermined significance (AUS) category is heterogeneous, leading to variations in its use. To prevent excessive usage, the AUS rate should be ≤10%. Although this recommendation aims to maintain diagnostic quality, it lacks supporting data. The AUS:Malignant (AUS:M) ratio has been proposed as a metric tool to evaluate AUS use. Furthermore, integrating ThyroSeq v3 (TSV3) positive call rate (PCR) and the molecular-derived risk of malignancy (MDROM) have been put forward as performance improvement tools. The authors reviewed their AUS:M ratios, TSV3 PCR, MDROM, and ROM.
Thyroid aspirates evaluated in the laboratory (from August 2022 to September 2023) by seven cytopathologists (CPs) were identified. AUS:M ratio, MDROM, ROM, and TSV3 PCR results for the laboratory and each CP were recorded and analyzed.
A total of 2248 aspirates were identified (462 AUS and 80 malignant). The AUS:M ratio for the laboratory was 5.8 (CPs range, 2.8 to 7.3). The TSV3 PCR for the laboratory was 23% (CPs range, 11% to 41%). The MDROM for the laboratory was 19% (CPs range, 9% to 31%), whereas the ROM was 36% (CPs range, 29% to 50%). Linear regression analysis of AUS:M ratio versus TSV3 PCR and MDROM demonstrated a moderate positive correlation but a weak negative correlation to the ROM. Deviations from established targets were attributed to multiple factors.
The findings of this study underscore the importance of using a combination of metrics to evaluate diagnostic practices. By dissecting the practice patterns of each CP, the authors can measure different aspects of their performance and provide individualized feedback.
意义未确定的不典型(AUS)类别具有异质性,导致其使用存在差异。为了防止过度使用,AUS 率应≤10%。尽管这一建议旨在保持诊断质量,但缺乏支持数据。AUS:恶性(AUS:M)比值已被提议作为评估 AUS 使用的度量工具。此外,还提出了 ThyroSeq v3(TSV3)阳性检出率(PCR)和分子恶性风险(MDROM)作为提高性能的工具。作者回顾了他们的 AUS:M 比值、TSV3 PCR、MDROM 和 ROM。
确定了实验室(2022 年 8 月至 2023 年 9 月)由七名细胞病理学家(CPs)评估的甲状腺抽吸物。记录并分析了实验室和每位 CP 的 AUS:M 比值、MDROM、ROM 和 TSV3 PCR 结果。
共确定了 2248 份抽吸物(462 份 AUS 和 80 份恶性)。实验室的 AUS:M 比值为 5.8(CPs 范围为 2.8 至 7.3)。实验室的 TSV3 PCR 为 23%(CPs 范围为 11%至 41%)。实验室的 MDROM 为 19%(CPs 范围为 9%至 31%),而 ROM 为 36%(CPs 范围为 29%至 50%)。AUS:M 比值与 TSV3 PCR 和 MDROM 的线性回归分析显示出中度正相关,但与 ROM 呈弱负相关。偏离既定目标归因于多种因素。
本研究的结果强调了使用组合指标评估诊断实践的重要性。通过剖析每位 CP 的实践模式,作者可以衡量其表现的不同方面,并提供个性化的反馈。